# PATIENTS WITH SOFT TISSUE SARCOMA AFTER TREATMENT BY NON ORTHOPEDIC ONCOLOGIC SURGEONS: EPIDEMIOLOGICAL PROFILE, STAGING, AND THERAPEUTIC CHALLENGES

## TL;DR

This study examines soft tissue sarcoma patients treated by non-orthopedic oncologists, highlighting high recurrence and mortality rates.

## Contribution

The study provides insights into treatment challenges and outcomes for soft tissue sarcoma patients managed outside specialized orthopedic oncology settings.

## Key findings

- Most patients had high-grade tumors, with synovial sarcoma and undifferentiated pleomorphic sarcoma being the most common subtypes.
- High recurrence (77%) and metastasis (49.2%) rates were observed, with lungs as the primary metastatic site.
- A mortality rate of 47.5% was recorded, emphasizing the need for specialized and multidisciplinary care.

## Abstract

this study analyzed patients with soft tissue sarcoma treated by non-orthopedic oncologists, evaluating their epidemiological profile, staging, and therapeutic challenges.

an analytical study in the form of a retrospective cohort, conducted through a review of medical records of patients treated at the hospital from January 1, 2011, to December 31, 2021.

a total of 61 patients were included, mostly male (55.7%), with a mean age of 42.8 years. The most frequent histological subtypes were synovial sarcoma (29.5%) and undifferentiated pleomorphic sarcoma (21.3%), with a predominance of high-grade tumors (75.4%). The majority of cases (77%) underwent resection, but without proper planning, leading to high recurrence rates (77%) and metastases (49.2%), with the lungs being the primary metastatic site. The mortality rate was 47.5%, with an average time to death of 3.1 years.

the findings highlight the need for early diagnosis, specialized treatment, and multidisciplinary management to optimize clinical outcomes for patients. The adoption of standardized protocols in referral centers may reduce inadequate interventions and improve survival and quality of life for patients with soft tissue sarcoma.
Level of Evidence III; Retrospectivef comparative studye

.